Sino Biopharmaceutical (HKG:1177) obtained approval for marketing for Rivastigmine Transdermal Patch from the National Medical Products Administration of China, a Wednesday Hong Kong bourse filing said.
Trading under the name Debaitai, the patch is for the treatment of symptoms of mild-to-moderate Alzheimer's disease, a neurodegenerative condition with severe onset and progressive impairment, and a major cause of senile dementia.
Rivastigmine transdermal patch can supply a sustained and stable release of drug over a longer period, even for the patients who can not take oral medicines.
Price (HKD): $3.43, Change: $-0.030, Percent Change: -0.87%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。